ERBB2 and cancer: Cellular responses to HER2/neu-derived peptides are also detectable in PBMCs from both cancer patients and HDs, whereas humoral responses to those HER2/neu peptides were not reported (Fisk et al, 1995; Peoples et al, 1995; Kawashima et al, 1999; Okugawa et al, 2000).